TLDR:
– Diamond Biofund, a venture capital firm in Taiwan, has delivered a 17 times return to investors in a decade.
– The fund is backed by billionaires Daniel and Richard Tsai, Thomas Wu, and Samuel Yin.
Diamond Biofund, a venture capital firm based in Taipei, is making significant strides in driving innovation in Taiwan’s biotechnology sector. Founded in 2013, the fund has delivered a remarkable 17 times return to investors in just a decade. This success has greatly benefited the four billionaires who initially invested in the fund, including Daniel and Richard Tsai, Thomas Wu, and Samuel Yin.
The fund has supported and invested in over 20 biotech and healthcare companies, one of which includes Oneness Biotech, a new drug developer for dermatology and immunology disorders. This particular company went public in 2011 and currently boasts a market cap of over $2 billion.
Samuel Yin, one of the founding partners of Diamond Biofund, expressed his ambitious vision for the biotechnology sector in Taiwan back in 2013. He envisioned Taiwan embracing a new era for biotech similar to the success of its semiconductor industry.
In a significant move, Diamond Biofund became the first venture capital firm to list on the island in September, raising NT$4 billion. This milestone highlights the fund’s commitment to driving innovation and growth in Taiwan’s biotechnology sector.
